Pain, Intractable
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Sorrento TherapeuticsCA - San Diego
2 programs1
1
ResiniferatoxinPhase 31 trial
ResiniferatoxinPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Sorrento TherapeuticsResiniferatoxin
Sorrento TherapeuticsResiniferatoxin
Spine BioPharmaDorsal Root Ganglion Stimulation
Clinical Trials (3)
Total enrollment: 135 patients across 3 trials
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Start: Dec 2020Est. completion: Mar 20230
Phase 3Withdrawn
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Start: Sep 2025Est. completion: Dec 2027120 patients
Phase 2Suspended
Intermittent vs. Continuous Dorsal Root Ganglion Stimulation
Start: Mar 2021Est. completion: Sep 202115 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.